Blaine M. Hackman Ph.D.

Blaine M. Hackman, Ph.D. currently focuses his practice on U.S. Patent and Trademark Office post-grant proceedings, patent litigation, and patent counseling, and prosecution. Dr. Hackman has represented pharmaceutical and biotechnology clients in Inter Partes Review (IPR) and Post-Grant Review (PGR) proceedings before the Patent Trial and Appeal Board (PTAB). Dr. Hackman has also represented pharmaceutical and biotechnology clients in intellectual property litigation (including Hatch-Waxman proceedings) and advised on patent issues for numerous transactions. He has also prosecuted patents and counseled clients in transactions in a variety of technologies, including small molecule and protein therapies, nanotechnology, diagnostic imaging, and analytical chemistry.

Dr. Hackman has published, presented, and provided insights on intellectual property-related issues, including publications for Reuters on the legacy of Judge Prost’s opinions and dissents related to life... Continue Reading

Petitioner, Kymera Therapeutics in a PGR (PGR2021-00115) of USPN 10,849,980, titled “Methods to Induce Targeted Protein Degradation through Bifunctional Molecules.”
Petitioner BicycleRD in IPR (IPR2020-01569 and IPR2020-01626) of USPNs 8,748,105 and 8,742,070, titled “Method for Selecting a Candidate Drug Compound.”
Petitioner, Eli Lilly & Co., in a PGR (PGR2019-00043) of USPN 10,011,654, entitled “Antibodies Directed to IL-17A/IL-17F Heterodimers.”
Pfizer in securing reissue patent RE47,739 in the U.S. Patent and Trademark Office related to its blockbuster cancer treatment, IBRANCE® (palbociclib).
Royalty Pharma in several transactions, including those relating to Risdiplam, Seltorexant, Vertex’s cystic fibrosis treatments, IDHIFA® (enasidenib), ENTYVIO® (vedolizumab), PREVYMIS™ (letermovir), TAZVERIK® (tazemetostat), and PROMACTA® (eltrombopag).
A major medical device company as Patent Owner in four IPR proceedings related to patents claiming a minimally invasive continuous glucose monitoring system (CGMS).

Drugmakers Undercut Rivals With New Patent Tactic as Law Shifts - Bloomberg Law (October 26, 2021)
Chief Judge Prost: a defender of clarity in patent law - Reuters (June 21, 2021)
Fintiv Rule Challenges Face Long Odds After Fed. Circ. Ruling - Law360 (March 16, 2021)
PTAB Sees Fewer Drug Patent Fights as Generics’ Strategy Shifts - Bloomberg Law (February 8, 2021)

Connect

+1 917 388 8306
blaine.hackman@dechert.com Send email
vCard
New York Office

Three Bryant Park, 1095 Avenue of the Americas, New York, NY, United States of America 10036-6797
- +1 917 388 8306
- +1 212 698 3599

Services

Patent Litigation

Patent Counseling and Prosecution

Hatch-Waxman Litigation

IP and Technology Licensing and Transactions

Intellectual Property

Industries

Life Sciences

Chemical

- Harvey Mudd College, B.S., 2001, High Honors, Dow Chemical Foundation Scholar
- Columbia University, Ph.D., 2006
- Georgetown University Law Center, J.D., 2013
- New York
- United States Patent and Trademark Office
- United States Court of Appeals for the Federal Circuit
- Patent Trial and Appeal Board (PTAB) Bar Association
- New York Intellectual Property Law Association (NYIPLA)
- American Chemical Society